Neuro-immune interactions enable mutual regulation of the nervous and immune systems. To date, evidence exists for manipulations of immune cells by neurotransmitters in the periphery. In this study, we suggest the existence of a pathway by which the brain affects immune cells. The pathway we describe here is mediated by dopamine receptors expressed on activated T cells, termed blasts. Blasts can cross the blood brain barrier regardless of antigen specificity and can therefore encounter neurotransmitters in the brain. We show that blasts have a unique response to dopaminergic activation, which has no counterpart in resting T cells. Dopaminergic activation of blasts induces a Th1 bias in their cytokine profile and causes changes in surface marker expression. We further suggest that these changes can subsequently be transferred to peripheral T cells. We have tested this pathway in two in vivo systems: in rats exogenously administered with L-dopa, and in schizophrenia, which is characterized by a central nervous system-restricted increase in dopamine. In both models, peripheral T cells exhibit similar features to those of dopaminergically activated blasts. The existence of such a pathway by which the brain can regulate immune cells opens a conceptually new direction in neuro-immune interactions.
egulation of immune system activities by other organs is primarily achieved through interactions with receptors expressed on immune cells. Among the various receptors on immune cells, the existence of receptors for neurotransmitters is surprising as the mechanism and site of receptor/ligand interaction remain unclear. The brain, where neurotransmitters are synthesized and secreted, is considered an immune-privileged organ where the blood brain barrier (BBB) tightly prevents lymphocyte entry (1, 2) . It was therefore believed that lymphocytes could not encounter neurotransmitters in the brain. Thus, most studies have concentrated on activation of these receptors by neurotransmitters in the periphery. The effects of the neurotransmitter dopamine (DA) on immune cells were of major interest because of the presence of dopamine receptors on T cells (3) (4) (5) . Recent studies described inhibition of T cell proliferation, changes in cytokine secretion, and apoptosis induced by DA (6) (7) (8) (9) (10) . Various peripheral mechanisms have been proposed to explain these effects, ranging from binding of DA secreted from peripheral nerve endings (11, 12) to autocrine-synthesis of DA by lymphocytes (13) . However, physiological concentrations of DA in the blood are orders of magnitude lower than what was used in these in vitro studies (11, 14) . Other studies demonstrated that increased plasma levels of DA exist in cancer patients and under chronic form of stress (14, 15) . In vitro exposure of T cells to such higher concentrations of DA resulted in the inhibition of T cell proliferation and of cytokine secretion (16) .
In this study, we have examined a new hypothesis on regulation of peripheral T cells by dopamine in the brain. Our decision to pursue this direction was initially based on some recent studies showing that activated T cell blasts can cross the BBB (17) . Blasts can enter the brain regardless of their antigen specificity, due to high expression of adhesion molecules (1, 17, 18) . Such blasts can therefore encounter and bind neurotransmitters in the brain, thus providing a possible explanation for the function of neurotransmitter receptors on T cells. To explore brain effects on immune cells through their receptors for neurotransmitters, we chose the neurotransmitter DA. T cells have previously been shown to express dopamine receptors D 3 , D 4 , and D 5 but not D 1 or D 2 (3) . In this study, we focused on the D 3 receptor (D 3 R) as a representative dopaminergic receptor. We show that dopaminergic activation of blasts induces a T-helper 1 (Th1) bias in their cytokine profile and causes changes in surface marker expression. These changes can be further transferred to peripheral resting T cells, thus suggesting a neurotransmitter-mediated brain regulation of peripheral T cells.
MATERIALS AND METHODS

Reagents and antibodies
Mouse monoclonal anti-human CD3, CD4, CD8, CD16, CXCR3 (PharMingen, San Diego, CA), CD25 (Serotec, Raleigh, NC) and the HP1/2 mAb specific for the 4-integrin subunit (19) were used as purified IgGs. Flourescein isothiocyanate-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Bar Harbor, ME) was used as secondary antibody. Mouse monoclonal anti-rat CD25 and VLA-4 were used as purified IgGs and were flourescein isothiocyanate-conjugated (Serotec). Quinpirole, butaclamol, U-99194A maleate, cholera toxin (CTX), pertussis toxin (PTX), L-dopa, and carbidopa were purchased from Sigma (St. Louis, MO). Female Lewis rats, 6 wk of age, were from the Animal Breeding Center of the Weizmann Institute of Science.
Cells
Human peripheral blood lymphocytes (PBL) from healthy donors were isolated from citrateanticoagulated whole blood by dextran sedimentation and density separation over FicollHypaque. The mononuclear cells so obtained were washed and further purified by nylon wool and plastic adherence as previously described (20) . The resulting PBL were >90% CD3 + T lymphocytes; the remaining cells were NK cells, which neither express D 3 R (unpublished data) nor are affected by dopamine (21) . To stimulate blast formation, we incubated T cells in phytohemagglutinin (PHA) (5 µg/ml) and interleukin (IL)-2 (100 U/ml) enriched medium for 48 h followed by 72 h incubation in IL-2-enriched medium. After 5 days of in vitro activation, >95% of the cells were CD3 + T cell blasts expressing high levels of VLA-4 as compared with nonactivated T cells. 
Accumulation of cAMP
The assay was performed as described previously (22) with slight modifications; the cells were incubated in RPMI medium. Preincubation with PTX (130 ng/ml 16-18 h) or CTX (20 µg/ml 16-18 h) was performed to abolish Gi-or Gs-protein activity, respectively.
Reverse transcriptase-polymer chain reaction (RT-PCR) for D 3 R and cytokines
RT-PCR analysis was performed essentially as described previously (24) . Total RNA was isolated from lymphocytes using the TRI reagent method according to the manufacturer's instructions (Molecular Research Center, Cincinnati, OH). For PCR, 2 µg of total RNA were reverse transcribed into first-strand cDNA and 2 µl of the cDNA product (80 ng RNA) was used for PCR.
The primer sequences and amplification conditions were as follows: human: β-actin, 5′ TGAAGTGTGACGTGGACATCCG and 3′ GCTGTCACCTTCACCGTTCCAG, 23 cycles with an annealing temperature of 60°C; D 3 , 5′ AGGAGACGGAAAAGGATCCTCAC and 3′ TCAGCAAGACAGGATCTTGAGGAA, 38 cycles with an annealing temperature of 60°C; IFN-γ, 5′ TTTGGGTTCTCTTGGCTGTTACTG and 3′ TGCTTTGCGTTGGACATTCAAG, 30 cycles with an annealing temperature of 60°C; IL-4, 5′ AGTGCGATATCACCTTACAGGAGA and 3′ ATGATCGTCTTTAGCCTTTCCAAGA, 32 cycles with an annealing temperature of 60°C; IL-10, 5′ CTGTTGCCTGGTCCTCCTGACTGG and 3′ CATGCGCCTTGATGTCTGGGTCTTGG, 30 cycles with an annealing temperature of 60°C; Rat: β-actin, 5′ TACTGCCCTGGCTCCTAGCA and 3′ TGGACAGTGAGGCCAGGATAG, 23 cycles with an annealing temperature of 60°C; D 3 , 5′ AGGCAAAGAAAACGGATCCTCAC and 3′ TGCTTGACAGTGGGTATTAAGAACG, 38 cycles with an annealing temperature of 64°C; IFN-γ, 5′ GCTCTGCCTCATGGCCCTCTCTGGC and 3′
GCACCGACTCCTTTTCCGCTTCCTT, 30 cycles with an annealing temperature of 60°C; IL-4, 5′ CCCCAGGCAGAGAACCATGGCCCA and 3′ GCCCCCACCTTGCTGTCACCCTG, 34 cycles with an annealing temperature of 60°C. The PCR products obtained were separated on 1% agarose gel and confirmed by sequence analysis (24) .
Immunoflurescence flow cytometry
Cells were washed once with PBS, resuspended in FACS wash buffer (PBS, 5% bovine serum albumin, and 0.05% sodium azide), and incubated with primary antibodies (10 µg/ml) for 30 min at 4°C. Following washing, the cells were incubated with secondary antibodies for 30 min at 4°C, washed again, and analyzed immediately on a FACScan flow cytometer.
Analysis of T cells from rats
Female Lewis rats were injected i.p. (six rats in each group) with either saline as a control, 10 mg/kg carbidopa, or a mixture of 30 mg/kg L-dopa and 10 mg/kg carbidopa. This low concentration of L-dopa was previously shown to have no effect on human lymphocytes (13) .
Injections were administered daily for 1 or 3 wk, after which three rats for each treatment group were anesthetized by CO 2 , and blood was collected by retro-orbital bleeding and pooled for each treatment group. T cells were isolated from total blood as described above. Rats were then killed by decapitation, and brains were rapidly removed, and the striatum was dissected on ice and immediately frozen in liquid nitrogen. T cells were analyzed by FACS for the expression of surface markers, and mRNA levels of several genes were determined. Striatal tissue was homogenized using sonicator in 200 µl 0.1 N perchloric acid and then centrifuged 10 min at 13,000 rpm at 4°C. The supernatant was filtered and analyzed for dopamine by HPLC with electrochemical detection (25) . Protein concentration was determined for each sample. Animal care and use was approved by the institutional review committee.
RESULTS
Although it has been known for several years that DA receptors are expressed on T cells (3) (4) (5) , their functional activity and direct coupling to a signal transduction pathway is not well understood. To test the functionality of dopamine receptor on T cells, we measured cAMP accumulation in resting T cells and blasts derived from them, following dopaminergic activation with quinpirole, a D 2 /D 3 agonist. D 3 dopamine receptor (D 3 R) has been previously shown to couple to both inhibitory and stimulatory G proteins (Gi and Gs) in COS cells (26) . Thus, we have measured the coupling of D 3 R in human lymphocytes and blasts to each pathway independently, using the selective inhibitors pertussis toxin (for Gi) or cholera toxin (for Gs). As can be seen in Figure 1A , D 3 R in resting T cells coupled to both Gi and Gs pathways, as previously demonstrated in COS cells (22) , resulted in changes in cAMP accumulation. For both pathways, the coupling was abolished upon addition of the D 3 antagonist, U-maleate. In blasts, however, the changes in cAMP accumulation, following dopaminergic activation, were greater than in resting T cells when measured in either the stimulatory or inhibitory pathways (Fig. 1A) .
We have also measured mRNA levels of D 3 R, before quinpirole exposure in both resting T cells and blasts and demonstrated that they were higher in blasts than in resting T cells (Fig. 1B) , implicating elevated basal expression of D 3 R.
To determine whether D 3 R activation in resting T cells and blasts affects their immunological properties, we tested the effect of quinpirole on cytokine expression. To this end, RT-PCR analysis of IFN-γ, IL-4, and IL-10 was performed. As can be seen in Figure 2A , dopaminergic activation had no effect on cytokine levels of resting T cells. mRNA levels of all three cytokines tested were undetectable in resting T cells, before quinpirole treatment, and they remained undetectable following activation. Blasts, on the other hand, were different from resting T cells and responded to dopaminergic treatment by changes in cytokine expression. Before exposure to quinpirole, blasts expressed high levels of IL-4 and IL-10 and undetectable levels of IFN-γ. Quinpirole treatment resulted in marked changes in the cytokine expression of blasts. IL-4 and IL-10 were reduced to undetectable levels, while IFN-γ levels demonstrated an increase. The change in cytokine profile of blasts following quinpirole was abrogated upon addition of the D 3 R inhibitor, U-maleate (Fig. 2B) , demonstrating that the effect is mediated through D 3 R.
The changes in cytokine expression in blasts shown in Figure 2A were observed after an 8 h exposure to quinpirole. Because it is unclear whether under physiological conditions blasts that enter the brain are exposed to DA for such a length of time (27) (28) (29) , we have tested whether a short exposure to the dopaminergic ligand quinpirole could trigger the same immune response.
We have observed that even a short exposure (20 min) of blasts to quinpirole followed by a subsequent incubation (3-9 h) of the cells with quinpirole-free medium, was sufficient to induce an increase in mRNA levels of IFN-γ (data not shown).
A switch in cytokine expression from IL-4 and IL-10 to IFN-γ is usually associated with a Th2 to Th1 shift of CD4 T cells (30) . However, because IFN-γ is also secreted by CD8 T cells (31), the observed switch could also be attributed to CD8 T cell activation. To determine which subset of cells participate in this change, we isolated CD4 and CD8 T cells. Both subsets of cells express D 3 R mRNA (data not shown). Blasts were then induced from the two cell subsets, and the effect of D 3 R activation with quinpirole on their cytokine expression was measured (Fig. 2C) . Dopaminergic activation affected differentially the CD4-and CD8-derived blasts. For the CD4 blasts, the switch in cytokine profile was the same as that observed for the total blast population, namely, a switch from pronounced IL-4 and IL-10 levels and negligible IFN-γ levels, to negligible IL-4 and IL-10 and pronounced IFN-γ levels. CD8 blasts, on the other hand, had essentially undetectable mRNA levels of all three cytokines before treatment and demonstrated increased levels of only IFN-γ in response to quinpirole. This finding suggests that, when exposed to quinpirole, CD4 blasts undergo a Th2 to Th1 shift, and CD8 blasts are triggered to produce IFN-γ.
Expression of integrins and other receptors mediating cell activation and trafficking is another fundamental aspect of the immune cell response. We therefore examined the effect of D 3 R activation in resting T cells and blasts on the expression of three surface markers: VLA-4 (an α−4 integrin), which is involved in blast recruitment and crossing of the BBB (1, 32); CD25 (IL-2R α chain), a classical activation marker (28, 33) ; and CXCR3, a principal inflammatory chemokine receptor, involved in trafficking of T cells to the central nervous system (CNS) (34) . The effect of quinpirole on these molecules was tested in resting T cells and blasts (Fig. 2D) .
Resting T cells exhibited low expression levels of all three molecules, whereas blasts, due to their increased activation state, expressed them more intensely. Dopaminergic activation of resting T cells had no significant effect on the expression of all three molecules. However, the exposure of blasts to quinpirole led to an increase in CD25 expression, a decrease in CXCR3, and no detectable change in VLA-4 levels. Both the increase in CD25 and the decrease in CXCR3 expression were abrogated by the dopaminergic antagonist U-maleate (Fig. 2D ). These results demonstrate another aspect of D 3 R-mediated alteration in the immune response of blasts. As for cytokine expression, also for surface markers, only activated blasts and not resting T cells responded to dopaminergic activation.
It was of interest to find out whether a change in the brain could affect immune cells in vivo and whether these effects could be transferred to the peripheral immune system. To this end, two model systems were tested. In the first one, rats were injected with L-dopa/carbidopa, a treatment known to elevate dopamine levels exclusively in the CNS (35) , and their peripheral T cells were analyzed (Fig. 3A, 3B ). Higher brain dopamine levels were verified using HPLC. Thus, the amount of dopamine in brains of rats treated with L-dopa/carbidopa was 576±129 ng/mg protein, and 232±60 and 282±15 ng/mg protein in rats injected with carbidopa alone, or with PBS, respectively. We found that peripheral T cells from rats treated for 1 wk (Fig. 3 ) or 3 wk (data not shown) with L-dopa/carbidopa had similar features to those of dopaminergically activated human blasts (see Fig. 2 ), namely, higher mRNA expression of INF-γ and D 3 R, and also higher levels of VLA-4 and CD25, as compared with control groups. Thus, the observed changes in peripheral immune cells resulted most probably from changes in DA levels in the brain.
For the second in vivo model system, we looked at peripheral T cells from schizophrenia patients. Schizophrenia can serve as a natural human model for a CNS-restricted increase in DA, because the prevailing theory of schizophrenia suggests an excessive activity at dopaminergic synapses in specific brain regions (36) . Previously, we showed that D 3 R mRNA levels in lymphocytes of schizophrenic patients are higher (an average increase of 3.6-fold) than those of healthy controls (24) . This change is similar to the increase observed in the present study in human blasts vs. resting T cells (2.2±0.6-fold increase, calculated from Fig. 1B) . To further characterize changes in peripheral T cells from schizophrenia patients, cAMP accumulation following quinpirole treatment was determined in T cells from schizophrenia patients and from healthy controls. As can be seen in Figure 4 , there was a higher increase in quinpirole-induced cAMP accumulation in T cells from schizophrenia patients than in T cells from healthy individuals (average of 79% and 9%, respectively). This is similar to the increase in activity that was observed in blasts vs. resting T cells from normal humans (Fig. 1A) . This substantial increase in quinpirole-induced cAMP accumulation in schizophrenia patients may reflect the higher proportion of activated peripheral T cells. In this respect, it should be mentioned that recent studies have demonstrated that lymphocytes from schizophrenia patients exhibit elevated CD25 expression and IL-2 and IFN-γ serum levels (37) (38) (39) . In addition, a decrease in D 3 R mRNA levels and IFN-γ secretion was demonstrated in peripheral lymphocytes from Parkinson's disease patients (40, 41) . These findings suggest that the proposed mechanism functions also when CNS DA levels are decreased, leading to the countereffect on peripheral cells than that observed in schizophrenia. Taken together, these results further support our suggestion that changes in dopamine in the CNS induce alterations on immune cells in the periphery. However, this preliminary conclusion awaits a detailed analysis of immune cells in schizophrenia patients.
In an attempt to elucidate the mechanism by which increased DA levels in the CNS can affect peripheral T cells, we have examined whether blasts can affect resting T cells through soluble factors they secrete. This is based on the findings that cytokines secreted by blasts can drain through the cerebrospinal fluid (42) . To this end, blasts derived from human lymphocytes were incubated for 24 h with or without quinpirole, followed by an additional incubation for 24 h in quinpirole-free medium to remove quinpirole. Supernatant was then separated from blasts, and freshly isolated T cells were incubated with the blast supernatant. Supernatant-induced changes in resting T cell mRNA levels of IFN-γ, IL-4, and IL-10 were then measured (Fig. 5) . Supernatant of untreated blasts induced IL-4 and IL-10 expression in resting T cells (Fig. 5, lane  C) , as is the case in the untreated blasts (Fig. 5, lane A) . On the other hand, supernatant of quinpirole-treated blasts, induced only IFN-γ (Fig. 5, lane D) , similar to what has been observed in blasts treated with quinpirole ( Fig. 2A) . Thus, the supernatant-induced alterations in cytokine profile of resting T cells reflected the cytokine profile of the blasts from which the supernatants have been derived (Fig. 2A, Fig. 5 ). Although still suggestive, these data with blast supernatants may indicate that dopaminergically activated blasts could trigger T cells to mimic their properties by means of soluble factors.
DISCUSSION
The existence and function of receptors for neurotransmitters on immune cells is still enigmatic. It was commonly assumed that immune cells do not cross the BBB and can therefore encounter neurotransmitters only in the periphery. Thus, in previous studies, only peripheral mechanisms for neurotransmitter effects on T cells were considered. Several studies looked at the effects of DA on T cells and demonstrated that DA down-regulates cytokine expression, inhibits cell proliferation, and even leads to apoptosis (16) . However, in some of these studies, nonphysiological concentrations of DA have been used (43) . It is possible that the dopaminergic regulation of T cells described here is not restricted only to the brain; it may also involve some similar peripheral mechanism. Yet, to date, activation of peripheral dopamine receptors by circulating DA seems puzzling, due to its low peripheral concentrations. Circulating DA levels were shown to be in the order of picomolar to femtomolar and ~95% is in sulfoconjugate or glycoconjugate forms (43, 44) .
It was recently shown that highly activated T cells, termed blasts, can cross the BBB due to high expression of adhesion molecules and regardless of antigen specificity (18, 45) . Based on these findings, we propose the hypothesis that D 3 dopamine receptors on T cells participate in brain regulation of peripheral immune cells. We have examined this hypothesis in primary T cells and blasts that were isolated from human and rat. To stimulate D 3 R on T cells and blasts, we used quinpirole, a D 2 /D 3 ligand, throughout this study. Because these cells do not express the D 2 receptor (3), quinpirole treatment leads to the activation of only D 3 R. To verify our results, we performed some of the experiments using another D 3 ligand, 7-OH-DPAT, and the same effects were obtained (unpublished data).
Throughout this study, only blasts and not resting T cells were shown to be affected by dopaminergic ligands. Thus, it seems that dopaminergic regulation is mediated through activated T cell blasts that are able to cross the BBB. Once exposed to dopaminergic ligands, blasts undergo fundamental immunological changes, which may be transmitted to the periphery either by these cells leaving the CNS or via messenger-soluble factors.
Some earlier studies on experimental allergic encephalomyelitis (EAE) support our findings. Flugel et al. (28) have demonstrated that upon arrival in the CNS, antigen-specific T cells are reactivated and up-regulate activation markers such as CD25 and OX-40 antigen. Proinflammatory cytokines (i.e., IFN-γ) were also up-regulated in this study, whereas no change was observed in VLA-4 levels. These results present the same pattern of changes in T cells following invasion to the CNS as demonstrated by us in activated T cell blasts in response to dopamine and support our data. In another study, the EAE model was used to study CD4 T cells that have infiltrated the CNS (46) . CD4 cells specific for myelin basic protein that produce both Th1 and Th2 cytokines were transferred to mice. The cells were then reisolated from the CNS and analyzed for cytokine production. All the cells produced only Th1 cytokines, while cells that were isolated from lymph nodes produced both Th1 and Th2 cytokines. These are, again, the same CNS-induced features as the dopaminergically induced effects that we have observed in activated T cell blasts. It should be noted that in these studies murine T cells were stimulated through their T cell receptor, whereas in our study mitogen-activated blasts that were driven from freshly isolated peripheral human T cell were used. However, the effect of specific stimulation through T cell receptor on D 3 R levels and activity was not examined by us or by others.
Our in vitro findings are further supported by the in vivo experiments. Peripheral T cells isolated from rats that were injected with L-dopa/carbidopa demonstrated immunological properties that were identical to those of dopamine-induced human blasts. The same phenomena were also observed with peripheral T cells isolated from schizophrenia patients. Schizophrenia was chosen because the prevailing theory for this disease is that it results from an excessive dopamine activity in specific brain regions (36) , thus serving as a human model for increased brain dopamine levels. It is noteworthy that a decrease in D 3 R mRNA levels and IFN-γ secretion was demonstrated in peripheral lymphocytes from Parkinson's disease patients (40, 41) . This feature is opposite to what has been demonstrated by us in schizophrenia and in dopaminergically activated blasts, thus suggesting that the proposed mechanism may function also when CNS DA levels are decreased, as is the case in Parkinson's disease.
We propose here the existence of a "brain-to-T cells" pathway by which the brain could manipulate immune cells via affecting activated cells that have invaded the brain. The role of such a regulatory pathway is still not clear. The brain may affect invading immune cells in order to originate a response that will recruit more peripheral immune cells to affect cells within the brain. Alternatively, such a pathway may serve as an additional broad regulation of the immune system by the brain that integrates all inputs from the periphery. The differentiation between the two scenarios still needs to be determined. Yet, the fact that the organ that not long ago was considered as immune-privileged appears now to interact with and affect immune cells, suggests a conceptually new pathway of neuro-immune interactions.
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